NasdaqGM:ATRCMedical Equipment
Assessing AtriCure (ATRC) Valuation After Milestone First‑in‑Human Results for Its Dual Energy Ablation Platform
AtriCure (ATRC) just cleared an important milestone by reporting successful first in human procedures with its dual energy platform that combines Pulsed Field Ablation with Advanced Radiofrequency Ablation in cardiac surgery.
See our latest analysis for AtriCure.
That progress seems to be resonating with investors, with a roughly 34.7% year to date share price return and a 33.3% one year total shareholder return hinting that momentum is rebuilding after weaker multi year performance.
If this...